Siderosis treatment

Siderosis Treatment Provided by the Lung Institute

Treatment for siderosis and related conditions is offered at the Lung Institute, where we exclusively treat lung disease using innovative stem cell therapy. Siderosis, which is a type of interstitial lung disease, develops when iron particles are inhaled and deposited deep within the lungs. This condition is sometimes referred to as a benign form of pneumoconiosis, as it rarely causes symptoms like coughing and shortness of breath. Despite its lack of direct symptoms, however, siderosis can lead to other conditions that produce their own symptoms (including pneumonia and lung infections), which may require treatment.

The Lung Institute is proud to offer stem cell therapy for symptoms of the conditions related to siderosis. Our stem cell treatment procedures for siderosis can be performed using the following two methods, each of which offers certain advantages:

  • Bone marrow therapy — We remove stem cells from a patient’s bone marrow, which has been found to contain more adult stem cells than peripheral blood.
  • Venous therapy — We extract stem cells from a patient’s blood using a collection process that is less invasive than that used during bone marrow procedure.

When providing treatment using stem cells, we begin by removing a small sample of a patient’s blood or bone marrow. We then separate the stem cells from the sample. Finally, we return the concentrated stem cells to the patient’s blood through an intravenous infusion. Both of these siderosis stem cell treatment methods are performed in a clinical setting at one of our state-of-the-art facilities on an outpatient basis over the course of two days.

If you have been diagnosed with siderosis or a related condition and are interested in learning about the Lung Institute’s innovative stem cell treatment methods, please call us today at (800) 729-3065 so that we may answer your questions and provide you with additional information.

* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. The Lung Institute is firmly in accordance with the conditions set by the FDA for exemption status and conducts itself in full accordance with current guidelines. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and stem cell procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.